Skip to main content
. 2021 Mar;9(5):417. doi: 10.21037/atm-21-761

Figure 5.

Figure 5

BCKDK inhibitor (BT2) reduces the tumorigenic properties of PDAC cells. (A) The expression levels of BCKDK in various cancer tissues in the TCGA database in the GEPIA http://gepia.cancer-pku.cn/detail.php; (B) the final average tumor growth curve of mice injected with control or BCKDK inhibitor. **, statistically significant (P<0.01). BCKDK, branched-chain ketoacid dehydrogenase kinase; PDAC, pancreatic ductal adenocarcinoma; TCGA, The Cancer Genome Atlas.